T cell engaging bispecific mAb

Evolving from the triomab technology, LintonPharm has developed the next-generation proprietary bispecific antibody platform. The diversified CD3 candidate molecules have different affinity levels, and the TCE designs can adopt different CD3 to meet requirements in the complex tumor environment, which brings a strong guarantee for the high efficiency and low toxicity of TCE. The platform allows for the production of a recombinant bispecific antibody with key features including:

• Fully-humanized sequences with low immunogenicity (Human IgG).
• Specifically designed framework mutations to elevate anti-tumor long-lasting vaccinal effect.
• Low toxicity.
• Optimized cytoxicity.
• Strengthened protein stability.
• Break through the technical barriers of solid tumors.

The platform enables the bispecific antibodies to be generated in both symmetrical and asymmetrical formats, as demonstrated below.

We have established robust and efficient methods for antibody generation by combining the classic hybridoma and phage display antibody generation and discovery approaches with antibody engineering through structure-based rationale design. The platform is able to identify high-affinity antibodies, and create antibodies through in-silico design and experimental validation to minimize the antibody immunogenicity and enable long-term anti-cancer therapies with low toxicity.